# Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

> **NCT06255626** · PHASE1,PHASE2 · RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 215 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** CD40.RBDv vaccin (SARS-Cov2 Vaccin)

## Key facts

- **NCT ID:** NCT06255626
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-27
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 215 (ESTIMATED)
- **Last updated:** 2025-04-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06255626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06255626, "Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06255626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*